Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study

Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study

Background/Aim This study aimed to establish the real-world effectiveness and safety of grazoprevir/elbasvir (EBR/GZR) therapy in South Korea. Methods A total of 242 patients with chronic hepatitis C virus (HCV) genotype 1 or 4 infection who started EBR/GZR were consecutively enrolled from seven ter...

Full description

Bibliographic Details
Main Authors:	Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
Format:	Article
Language:	English
Published:	The Korean Association of Internal Medicine 2021-03-01
Series:	The Korean Journal of Internal Medicine
Subjects:	hepatitis c antiviral agents elbasvir-grazoprevir drug combination
Online Access:	http://www.kjim.org/upload/pdf/kjim-2019-357.pdf

Similar Items

Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C
by: Chun-Jen Liu, et al.
Published: (2020-05-01)

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
by: Jin Chen, et al.
Published: (2020-01-01)

Reduction of Liver Fibrosis After Treatment with Elbasvir/Grazoprevir in Patients with Hepatitis C Infection in Chronic Kidney Disease on Hemodialysis, a Quasi-Experimental Study
by: Bayu Laksono, et al.
Published: (2021-05-01)

A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
by: Li H, et al.
Published: (2020-02-01)

Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
by: Jinyu Liu, et al.
Published: (2022-05-01)

An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir–grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study)
by: Jean‐Pierre Bronowicki, et al.
Published: (2023-01-01)

Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
by: Sulejmani N, et al.
Published: (2018-05-01)

A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir
by: Kazuo Tarao, et al.
Published: (2017-11-01)

Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
by: Lin YC, et al.
Published: (2019-04-01)

The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial
by: Ahmad AlEid, et al.
Published: (2022-01-01)

Transient flare of psoriasis under direct‐acting antiviral therapy of chronic hepatitis C: A case report
by: Leona Dold, et al.
Published: (2022-03-01)

Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done
by: Susana Llerena, et al.
Published: (2019-01-01)

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
by: Youn Jae Lee, et al.
Published: (2019-12-01)

Spotlight on grazoprevir—elbasvir once-daily combination and its potential in the treatment of hepatitis C
by: Suraweera D, et al.
Published: (2016-06-01)

Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment
by: Lina Weiss, et al.
Published: (2018-02-01)

Grazoprevir/elbasvir combination therapy for HCV infection
by: Anaïs Vallet-Pichard, et al.
Published: (2017-01-01)

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
by: Morikawa K, et al.
Published: (2018-09-01)

CSF3 Is a Potential Drug Target for the Treatment of COVID-19
by: Chao Fang, et al.
Published: (2021-01-01)

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation
by: Meghan E. Sise, et al.
Published: (2020-04-01)

P64 Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir
by: N. Reau, et al.
Published: (2017-08-01)

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy
by: Hézode C, et al.
Published: (2019-11-01)

Development and Validation of new RP-HPLC Method for the Simultaneous Estimation of Elbasvir and Grazoprevir in Combined Pharmaceutical Dosage Form
by: P Seetharamaiah, et al.
Published: (2023-12-01)

Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam
by: Chizoba Nwankwo, et al.
Published: (2019-07-01)

Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function
by: Ute Eisenberger, MD, et al.
Published: (2019-01-01)

Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance
by: Deanna D. Hill, et al.
Published: (2023-03-01)

Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study
by: Regino P. Gonzalez-Peralta, et al.
Published: (2023-03-01)

Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
by: Pin-Nan Cheng, et al.
Published: (2021-08-01)

Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older
by: Steven Flamm MD, et al.
Published: (2019-01-01)

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection
by: Nancy Reau, et al.
Published: (2017-10-01)

Successful treatment of chronic hepatitis C virus infection with crushed elbasvir/grazoprevir administered through a nasogastric tube in a patient with hypoxic encephalopathy
by: Wen‐Cheng Chang, et al.
Published: (2022-01-01)

2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis C: WhatGraves’s New?
by: Kyung-Ah Kim
Published: (2018-06-01)

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study
by: G. Dore, et al.
Published: (2017-08-01)

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
by: Franck Maunoury, et al.
Published: (2018-01-01)

Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? – Indications for Treatment
by: Kyung-Ah Kim
Published: (2016-03-01)

Potential Antiviral Options against SARS-CoV-2 Infection
by: Aleksandr Ianevski, et al.
Published: (2020-06-01)

A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
by: Hsuan-Yu Hung, et al.
Published: (2021-09-01)

Effects of Temperature and Pressure on Acute Stroke Incidence Assessed Using a Korean Nationwide Insurance Database
by: Jae-Sung Lim, et al.
Published: (2017-09-01)

Identification and Tracking of Antiviral Drug Combinations
by: Aleksandr Ianevski, et al.
Published: (2020-10-01)

Effects of Statin Combinations on Zika Virus Infection in Vero Cells
by: Erica Españo, et al.
Published: (2022-12-01)

Metabolic syndrome awareness in the general Korean population: results from a nationwide survey
by: Hyun-Jin Kim, et al.
Published: (2024-03-01)